The study suggests that restoring the missing hydrophilic surfactant proteins, specifically protein D, may offer a disease-modifying approach beyond simply mitigating acute respiratory distress.
Endogenous surfactant is primarily composed of phospholipids and four distinct surfactant proteins: A, B, C, and D. For decades, commercially available animal-derived surfactants have contained only the hydrophobic proteins B and C, which are essential for reducing surface tension but lack the immune-related functions performed by the hydrophilic proteins A and D. Synthetic formulas have attempted to include recombinant versions of these proteins but have never successfully incorporated all four. The current study investigates whether the acute administration of rfhSP-D can counteract the inflammatory response triggered by mechanical ventilation, a known contributor to lung injury in premature infants.
The experimental design utilized a preterm lamb model, which shares many physiological characteristics with humans, including high genetic variability and similar environmental pregnancy exposures. Twenty-four lambs were delivered at 127 days of gestation via caesarean section, a timing equivalent to approximately 26 weeks of human gestation. The animals were supported via conventional mechanical ventilation for 300 minutes. The study included three groups: a control group, a delayed group, and a mixed group. All lambs received an initial dose of poractant alfa (Curosurf) at 15 minutes. The control group subsequently received saline, while the delayed and mixed groups received rfhSP-D at specific intervals to test different administration strategies.
In the mixed group, rfhSP-D was combined with the surfactant bolus at 15 minutes, followed by additional doses of rfhSP-D at 120 and 240 minutes. In the delayed group, rfhSP-D was instilled separately at 20, 120, and 240 minutes. This distinction was critical for understanding the interaction between the protein and the surfactant vehicle. Twenty-two lambs were included in the final analysis, with baseline characteristics matched between groups. Successful administration of rfhSP-D was confirmed by detecting SP-D levels in endpoint plasma and bronchoalveolar lavage (BAL) samples in the treated groups.
The primary physiological finding was an improvement in lung compliance in the rfhSP-D-treated groups. By 30 minutes, which is 10 to 15 minutes after the first dose of rfhSP-D, compliance had risen from 0.26 mL/cmH2O/kg in control lambs to 0.35 mL/cmH2O/kg in the mixed group and 0.34 mL/cmH2O/kg in the delayed group. This improvement translated into a reduction in the peak inspiratory pressure required to maintain appropriate tidal volumes, dropping from 33.0 cmH2O in the control group to 28.3 cmH2O in the mixed group and 29.1 cmH2O in the delayed group.
These mechanical benefits persisted throughout the study period. At the conclusion of the 300-minute ventilation period, mean compliance values were 0.28 mL/cmH2O/kg in the control group, 0.34 mL/cmH2O/kg in the mixed group, and 0.38 mL/cmH2O/kg in the delayed group. The authors noted that there were no significant differences in arterial pH or peripheral oxygen saturation between the groups across the study period. The reduction in required peak inspiratory pressure suggests that rfhSP-D exerts a direct benefit on the mechanical properties of the lung, potentially by altering the behavior of the surfactant film or the distribution of aeration.
Regarding inflammatory markers, the study found that the mixed group showed a reduction in all cell types in the bronchoalveolar lavage compared to the control group, with the neutrophil count being significantly reduced. However, no differences were observed in the levels of pro-inflammatory cytokine gene expression, including IL-6, IL-8, KC, MCP-1, TNF-α, and IL-1β, between the three individual groups. A pooled analysis of the mixed and delayed groups did reveal an overall effect of rfhSP-D in reducing pro-inflammatory cytokine gene expression compared to the control, indicating a potential anti-inflammatory benefit that was not apparent when the groups were analyzed separately.
Histological examination of the right lung demonstrated improved recruitment and better lung airspace in both the mixed and delayed groups compared to the control. The average alveolar airspace in the delayed group was significantly higher than in the control group. Interestingly, the physiological data appeared to follow the structural data rather than the cellular data. The delayed group had higher inflammatory cell counts in the BAL than the mixed group, yet it exhibited greater airspace and better-preserved lung architecture. This discrepancy highlights the complexity of interpreting acute injury responses in large animal models.
The authors suggest that the disconnect between inflammation and lung mechanics points towards a direct mechanical effect of rfhSP-D. SP-D is known to bind and aggregate surfactant phospholipid, which may alter the surface behavior of the surfactant film. In the mixed group, where rfhSP-D was delivered as a single bolus with the surfactant, the interaction between the protein and the vehicle may have changed how far either spread through the lung. In the delayed group, where the protein was instilled separately, the results favored separate instillation for lavage rfhSP-D levels, alveolar airspace, histology, and peak inspiratory pressure. This suggests that part of the observed benefit may be an effect of the delivery vehicle rather than solely the molecule itself.
The study acknowledges several limitations, primarily the small sample size, which is a common constraint in preterm lamb studies. Unlike small animal models, sheep share many uncontrollable variables with humans, such as maternal differences and environmental exposures. Injury and inflammation are temporal processes that often require larger sample sizes to detect consistent histological and cellular responses. The authors emphasize that these findings highlight the need for replication before translation to clinical trials. Despite these limitations, the study provides valuable insight into the potential anti-inflammatory and mechanical effects of rfhSP-D.
Preclinical studies have provided mechanistic rationale that targeting neutrophilic inflammation is a promising therapeutic approach to BPD, with diverse mechanisms including cytokine signaling and recruitment. SP-D has been shown to attenuate the formation of neutrophilic extracellular traps in response to bacterial lipopolysaccharide in vitro, suggesting a role in the immune modulatory toolbox of the protein. While the current study did not specifically investigate this effector mechanism, it may be one of the many roles of SP-D in modulating inflammation. The findings support the idea that restoring the hydrophilic surfactant proteins could be a significant step toward developing disease-modifying therapies for BPD.
Currently, there are no neutrophil-specific therapies approved for BPD, and exogenous surfactant has replaced the hydrophobic proteins for four decades without including the hydrophilic ones. This study represents the first serious attempt to put back what is naturally present in endogenous surfactant. Although true disease modification in BPD remains out of reach in preclinical models, the results warrant consideration in large animal studies prior to progression to clinical trials. The authors conclude that a series of trials focusing on safety, delivery, and acute biology will be required for clinical translation. The study underscores the importance of understanding the complex interplay between surfactant components, lung mechanics, and inflammation in the context of preterm birth.
Subject of Research: The need for SPeeD: can acute surfactant protein D administration reduce ventilator-induced inflammation?
Article Title: The need for SPeeD: can acute surfactant protein D administration reduce ventilator-induced inflammation?
Article References: Donnelly, F. N., Tingay, D. G., Sett, A., & Tsantikos, E. (2026). The need for SPeeD: can acute surfactant protein D administration reduce ventilator-induced inflammation?. Pediatric Research. https://doi.org/10.1038/s41390-026-05629-6
Image Credits: AI Generated
DOI: 10.1038/s41390-026-05629-6
Keywords: need, SPeeD, acute, surfactant, protein, administration, reduce, ventilator-induced, inflammation, scientific research
News Source: Harold Sullivan. (November 10, 2026). Surfactant Protein D Reduces Lung Inflammation in Preterm Lambs. Scienmag.



